Correlation between abnormal GSK3β, β Amyloid, total Tau, p-Tau 181 levels and neuropsychological assessment total scores in CKD patients with cognitive dysfunction: Impact of rHuEPO therapy

Vinothkumar, G.; Krishnakumar, Subramanian; Riya,; Venkataraman, P.

doi:10.1016/j.jocn.2019.08.073

Cited by 18 publications

(18 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…EPO slightly reduced this situation in the striatum and no effect was detected in the cortex or the hippocampus. Previous studies have reported that EPO, alone or combined with other treatments, may reduce tau phosphorylation associated to different cognitive disorders (Kang et al, 2010;Vinothkumar et al, 2019). Even though glycogen synthase kinase-3β inhibition reduces tau phosphorylation (Maqbool et al, 2016), enhances myelination, improves clinical recovery in a model of GM-IVH (Dohare et al, 2018a) and restores altered neurogenesis in preterm patients with intraventricular hemorrhage (Dohare et al, 2018b), the narrow effect in our studies limits further conclusions at this level.…”

Section: Discussioncontrasting

confidence: 55%

Erythropoietin Improves Atrophy, Bleeding and Cognition in the Newborn Intraventricular Hemorrhage

Hierro-Bujalance

Infante-Garcia

Sanchez-Sotano

et al. 2020

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

The germinal matrix-intraventricular hemorrhage (GM-IVH) is one of the most devastating complications of prematurity. The short-and long-term neurodevelopmental consequences after severe GM-IVH are a major concern for neonatologists. These kids are at high risk of psychomotor alterations and cerebral palsy; however, therapeutic approaches are limited. Erythropoietin (EPO) has been previously used to treat several central nervous system complications due to its role in angiogenesis, neurogenesis and as growth factor. In addition, EPO is regularly used to reduce the number of transfusions in the preterm infant. Moreover, EPO crosses the blood-brain barrier and EPO receptors are expressed in the human brain throughout development. To analyze the role of EPO in the GM-IVH, we have administered intraventricular collagenase (Col) to P7 mice, as a model of GM-IVH of the preterm infant. After EPO treatment, we have characterized our animals in the short (14 days) and the long (70 days) term. In our hands, EPO treatment significantly limited brain atrophy and ventricle enlargement. EPO also restored neuronal density and ameliorated dendritic spine loss. Likewise, inflammation and small vessel bleeding were also reduced, resulting in the preservation of learning and memory abilities. Moreover, plasma gelsolin levels, as a feasible peripheral marker of GM-IVHinduced damage, recovered after EPO treatment. Altogether, our data support the positive effect of EPO treatment in our preclinical model of GM-IVH, both in the short and the long term.

show abstract

Section: Discussioncontrasting

confidence: 55%

Erythropoietin Improves Atrophy, Bleeding and Cognition in the Newborn Intraventricular Hemorrhage

Hierro-Bujalance

Infante-Garcia

Sanchez-Sotano

et al. 2020

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

“…É interessante notar que 41% dos estudos são asiáticos (Japão [27][28][29][30][31][32][33] , China [34][35][36][37][38][39] , Taiwan [40][41][42][43][44] e India 45,46 ), 25% 65 .…”

Section: Discussionunclassified

“…Em indivíduos com DRC, a presença de anemia compromete a tolerância ao exercício, a qualidade de vida e a competência cognitiva. Na presente revisão encontramos 2 estudos que avaliaram a correção da anemia, por meio da reposição de ferro e/ou de eritropoietina, e observaram melhora significativa do DC 29,46 .…”

Section: Discussionunclassified

Disfunção cognitiva em doença renal crônica pré-dialítica: uma revisão sistemática

Pires¹,

Paula²,

Ezequiel³

et al. 2021

Rev Neurocienc

View full text Add to dashboard Cite

Introdução. No Brasil, a população com mais de 65 anos pode chegar a 25,5%, em 2060. Com o envelhecimento populacional ocorre um aumento da prevalência das doenças degenerativas, dentre as quais o comprometimento cognitivo (CC). Impacto semelhante é observado na doença renal crônica (DRC). Existem fatores fisiopatológicos comuns entre a DRC e o CC. Dentre pacientes com DRC, até 38% apresentam CC. Em relação à fisiopatologia das alterações cognitivas na DRC, os achados são controversos. Objetivo. Avaliar os estudos relacionados à disfunção cognitiva na população com DRC pré-dialítica. Método. Utilizamos as estratégias PRISMA. Selecionamos os unitermos “renal insufficiency, chronic” and “cognitive disfunction”, realizamos a revisão sistemática e não meta-análise dada a disparidade dos estudos. Utilizamos as bases de dados disponíveis de forma gratuita: PubMed, Scielo. A seleção dos artigos foi realizada por dois pesquisadores. Critérios de inclusão: apresentar resumo em língua portuguesa, inglesa, espanhola ou francesa; incluir pacientes em pré-diálise; utilizar avaliações clínicas e/ou laboratoriais e/ou de imagens. Resultados. Encontramos 116 artigos e avaliamos 51. Conclusão. O CC é frequente na DRC e a etiologia permanece em discussão. A maioria dos estudos é derivada de dados secundários de grandes coortes ou estudos transversais. Os instrumentos clínicos mais utilizados são o MEEM e o MoCA e de neuroimagem, a ressonância magnética. Poucos estudos avaliam a inflamação e as toxinas urêmicas. Os mecanismos do CC na DRC são diversos, nem sempre correlacionados, existindo uma grande lacuna no melhor entendimento da associação fisiopatológica destas duas importantes morbidades.

show abstract

“…Renal anemia is caused by insufficient EPO production by tubulointerstitial cells and the resistance of erythropoietic precursor cells to EPO due to the accumulation of uremic toxins and systemic inflammation (Batchelor et al, 2020). Vinothkumar et al (2019) reported that the phosphorylated tau protein concentration was lower in patients with CKD treated with EPO than subjects without EPO treatment. Anemia was associated with neuron function in patients with CKD.…”

Section: Role Of Hypoalbuminemia and Anemia In Esrd Patients With Cognitive Impairmentmentioning

confidence: 99%

The Role of Plasma Neurofilament Light Protein for Assessing Cognitive Impairment in Patients With End-Stage Renal Disease

Hou

Huang

et al. 2021

Front. Aging Neurosci.

View full text Add to dashboard Cite

Introduction: End-stage renal disease (ESRD) is defined as the irreversible loss of renal function, necessitating renal replacement therapy. Patients with ESRD tend to have more risk factors for cognitive impairment than the general population, including hypertension, accumulative uremic toxin, anemia, and old age. The association between these risk factors and the pathologic protein was lacking. Blood-based assays for detecting pathologic protein, such as amyloid beta (Aβ), total tau protein, and neurofilament light chain (NfL), have the advantages of being less invasive and more cost-effective for diagnosing patients with cognitive impairment. The aim of the study is to validate if the common neurologic biomarkers were different in ESRD patients and to differentiate if the specific biomarkers could correlate with specific correctable risk factors.Methods: In total, 67 participants aged >45 years were enrolled. The definition of ESRD was receiving maintenance hemodialysis for >3 months. Cognitive impairment was defined as a Mini-Mental State Examination score of <24. The participants were divided into groups for ESRD with and without cognitive impairment. The blood-based biomarkers (tau protein, Aβ1/40, Aβ1/42, and NfL) were analyzed through immunomagnetic reduction assay. Other biochemical and hematologic data were obtained simultaneously.Summary of results: The study enrolled 43 patients with ESRD who did not have cognitive impairment and 24 patients with ESRD who had cognitive impairment [Mini-Mental State Examination (MMSE): 27.60 ± 1.80 vs. 16.84 ± 6.40, p < 0.05]. Among the blood-based biomarkers, NfL was marginally higher in the ESRD with cognitive impairment group than in the ESRD without cognitive impairment group (10.41 ± 3.26 vs. 8.74 ± 2.81 pg/mL, p = 0.037). The concentrations of tau protein, amyloid β 1/42, and amyloid β 1/40 (p = 0.504, 0.393, and 0.952, respectively) were similar between the two groups. The area under the curve of NfL to distinguish cognitively impaired and unimpaired ESRD patients was 0.687 (95% confidence interval: 0.548–0.825, p = 0.034). There was no correlation between the concentration of NfL and MMSE among total population (r = −0.153, p = 0.277), patients with (r = 0.137, p = 0.583) or without cognitive impairment (r = 0.155, p = 0.333).Conclusion: Patients with ESRD who had cognitive impairment had marginally higher plasma NfL concentrations. NfL concentration was not correlated with the biochemical parameters, total MMSE among total population or individual groups with or without cognitive impairment. The concentrations of Aβ1/40, Aβ1/42, and tau were similar between the groups.

show abstract

Correlation between abnormal GSK3β, β Amyloid, total Tau, p-Tau 181 levels and neuropsychological assessment total scores in CKD patients with cognitive dysfunction: Impact of rHuEPO therapy

Cited by 18 publications

References 34 publications

Erythropoietin Improves Atrophy, Bleeding and Cognition in the Newborn Intraventricular Hemorrhage

Erythropoietin Improves Atrophy, Bleeding and Cognition in the Newborn Intraventricular Hemorrhage

Disfunção cognitiva em doença renal crônica pré-dialítica: uma revisão sistemática

The Role of Plasma Neurofilament Light Protein for Assessing Cognitive Impairment in Patients With End-Stage Renal Disease

Contact Info

Product

Resources

About